Does OLANZAPINE Cause Second primary malignancy? 24 Reports in FDA Database
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Second primary malignancy have been filed in association with OLANZAPINE (Olanzapine). This represents 0.1% of all adverse event reports for OLANZAPINE.
24
Reports of Second primary malignancy with OLANZAPINE
0.1%
of all OLANZAPINE reports
0
Deaths
14
Hospitalizations
How Dangerous Is Second primary malignancy From OLANZAPINE?
Of the 24 reports, 14 (58.3%) required hospitalization, and 23 (95.8%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OLANZAPINE. However, 24 reports have been filed with the FAERS database.
What Other Side Effects Does OLANZAPINE Cause?
Drug ineffective (5,139)
Weight increased (3,588)
Off label use (3,256)
Toxicity to various agents (3,175)
Somnolence (2,612)
Sedation (2,130)
Suicide attempt (2,116)
Confusional state (1,898)
Condition aggravated (1,810)
Overdose (1,765)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which OLANZAPINE Alternatives Have Lower Second primary malignancy Risk?
OLANZAPINE vs OLANZAPINE\SAMIDORPHAN L-MALATE
OLANZAPINE vs OLAPARIB
OLANZAPINE vs OLARATUMAB
OLANZAPINE vs OLECLUMAB
OLANZAPINE vs OLIVE OIL\SOYBEAN OIL